Every 8-K that Aehr Test Systems (AEHR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AEHR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEHR filings page.
Aehr Test Systems reported fiscal fourth quarter 2026 net revenue of $18.8 million, up from $14.1 million a year earlier, with GAAP net income of $1.4 million, or $0.04 per diluted share. Non-GAAP net income was $3.6 million, or $0.11 per diluted share. Quarterly bookings reached a record $60.7 million, backlog was $80.6 million, and effective backlog, including post-quarter bookings, was $100.6 million. Total cash, cash equivalents and restricted cash rose to $116.5 million, supported by $97.4 million in net proceeds from a public equity offering.
For fiscal 2026, net revenue was $50.0 million, down from $59.0 million in 2025, with a GAAP net loss of $7.1 million versus a $3.9 million loss previously; non-GAAP net income was $0.9 million. Operations used $3.3 million of cash. Management highlights strong demand across AI processors, silicon photonics and power semiconductors, including approximately $8 million of recent silicon carbide WaferPak orders and growing package-level burn-in for AI. For fiscal 2027, Aehr projects revenue between $130 million and $150 million, representing roughly 160%–200% year-over-year growth, and targets non-GAAP net income of 18%–22% of revenue, supported by its effective backlog of about $100 million and expanding customer programs.
Aehr Test Systems completed sales under its at-the-market equity offering program, generating aggregate gross proceeds of approximately $60.0 million from common stock issuances. The shares were sold under an effective Form S-3 shelf registration that registered up to $100.0 million of securities, using a prospectus supplement dated April 8, 2026.
Aehr Test Systems entered into an equity distribution agreement on April 8, 2026 with William Blair & Company and Craig-Hallum Capital Group to sell up to $60,000,000 of common stock through an at-the-market offering program. Sales will be made from time to time under an effective Form S-3 shelf registration and an April 8, 2026 prospectus supplement. The agents will use commercially reasonable efforts to place shares and will receive a commission of up to 3.0% of gross proceeds. Either the company or the agents can suspend or terminate the program upon written notice.
Aehr Test Systems reported third quarter fiscal 2026 net revenue of $10.3 million, down from $18.3 million a year earlier, as it posted a GAAP net loss of $3.2 million, or $(0.10) per diluted share. Non-GAAP net loss was $1.5 million, or $(0.05) per diluted share. Despite weaker revenue, Aehr booked $37.2 million of orders with a book-to-bill ratio over 3.5x, lifting backlog to $38.7 million, or $50.9 million including post-quarter bookings. Cash, cash equivalents and restricted cash were $37.1 million, up from $31.0 million in late November 2025. Management expects full-year fiscal 2026 revenue to be on the high side of its $45–$50 million outlook and reiterated second-half guidance of $25–$30 million revenue and non-GAAP net loss per share between $(0.09) and $(0.05), citing strong AI and data center demand.
Aehr Test Systems filed a current report to note that it issued a press release on January 8, 2026 announcing its financial results for the fiscal 2026 second quarter ended November 28, 2025. The company also used the release to communicate a reinstatement of its fiscal 2026 guidance. The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under certain securities laws.
Aehr Test Systems reported that stockholders approved amendments to two compensation plans at the company’s 2025 annual stockholders’ meeting held on October 20, 2025. The approvals cover the Amendment to the Amended and Restated 2006 Employee Stock Purchase Plan and the Amendment to the 2023 Equity Incentive Plan.
The company states that the terms of these amendments are set forth in the proxy statement dated September 10, 2025, which is incorporated by reference. The full texts of the amendments were filed as exhibits 10.1 and 10.2. This update was disclosed under Item 5.02 of an 8-K.
Aehr Test Systems reported results of its October 20, 2025 annual meeting. Of 29,968,988 shares entitled to vote, 20,156,704 were represented in person or by proxy.
Shareholders elected six directors. They approved an amendment to the 2023 Equity Incentive Plan to add 2,500,000 shares and an amendment to the Employee Stock Purchase Plan to add 300,000 shares. The selection of BPM LLP as independent registered public accounting firm for the fiscal year ending May 29, 2026 was ratified. A non-binding advisory vote approved executive compensation. On frequency, shareholders supported holding the advisory vote on executive compensation every 1 year, and the Board determined to adopt an annual cadence. The next required advisory vote on frequency will occur no later than the 2031 Annual Meeting.
Aehr Test Systems filed a current report to share that it has released its financial results for the fiscal 2026 first quarter, which ended on August 29, 2025. The company announced these results through a press release dated October 6, 2025.
The report explains that the press release is provided as an exhibit for informational purposes and is not treated as formally filed financial statements. The filing does not detail the actual revenue, earnings, or other performance figures, directing readers instead to the accompanying press release for the full fiscal 2026 first quarter financial results.